Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2004 > Volume 13 Number 6 November 2004 > MITRAL VALVE DISEASE > Prevalence and Fate of Severe Pulmonary Hypertension in 559 Consecutive Patients with Severe Rheumatic Mitral Stenosis Undergoing Mitral Balloon Valvotomy

Prevalence and Fate of Severe Pulmonary Hypertension in 559 Consecutive Patients with Severe Rheumatic Mitral Stenosis Undergoing Mitral Balloon Valvotomy

Mohamed Eid Fawzy, Walid Hassan, Miltiadis Stefadouros, Mohamed Moursi, Fayez El Shaer, Mohammad A. Chaudhary
Department of Cardiovascular Diseases and Biostatistics, Epidemiology & Scientific Computing Department Research Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Background and aim of the study: The prevalence of severe pulmonary hypertension (PH) in patients with severe mitral stenosis (MS) remains unknown, and the long-term effect of mitral balloon valvotomy (MBV) in large numbers of these patients is not well characterized.
Methods: Details from the prospective MBV database at the authors’ institution relating to 559 consecutive patients who had successful MBV were analyzed. Patients were allocated to three groups on the basis of their pulmonary artery systolic pressure (PASP) at cardiac catheterization immediately before MBV: group A (n = 345) had PASP <50 mmHg; group B (n = 183) had PASP 50-79 mmHg; and group C (n = 31) had PASP ≥80 mmHg. Patients were evaluated clinically and

echocardiographically at six months after MBV, and annually thereafter for up to 13 years.
Results: No mortality was encountered after MBV. Immediately after MBV, the mean PASP was 38.5 ± 6.8 mmHg in group A (mild PH), 59.0 ± 7.7 mmHg in group B (moderately severe PH), and 97.8 ± 17.0 mmHg in group C (severe PH). At follow up (ca. 4 years), Doppler-monitored PASP fell to normal, and was similar in groups A, B and C (29 ± 8, 31 ± 9, and 29 ± 5 mmHg, respectively; p = NS).
Conclusion: MBV was shown to be safe and effective in treating patients with MS and severe PH. The latter condition regressed to normal levels over 6-12 months after successful MBV.
The Journal of Heart Valve Disease 2004;13:942-948

Prevalence and Fate of Severe Pulmonary Hypertension in 559 Consecutive Patients with Severe Rheumatic Mitral Stenosis Undergoing Mitral Balloon Valvotomy

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.